# Study Evaluating Venetoclax in Subjects With Hematological Malignancies

> **NCT02265731** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 38 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** azacitadine
- **DRUG:** venetoclax
- **DRUG:** rituximab / IDEC-C2B8
- **DRUG:** rituximab / IDEC-C2B8

## Key facts

- **NCT ID:** NCT02265731
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-22
- **Primary completion:** 2021-03-12
- **Final completion:** 2021-03-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265731, "Study Evaluating Venetoclax in Subjects With Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02265731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*